Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study

• Published in: The American journal of clinical nutrition Vol. 77; no. 3; pp. 658 - 662
• Main Authors: VENN, Bernard J, GREEN, Timothy J, MOSER, Rudolf, MANN, Jim I
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Clinical Nutrition 01-03-2003; American Society for Clinical Nutrition, Inc
• Subjects: Adult; Biological and medical sciences; Clinical trials; Dietary Supplements; Double-Blind Method; Erythrocytes - chemistry; Feeding. Feeding behavior; Female; Folic Acid - administration & dosage; Folic Acid - blood; Food, Fortified; Fundamental and applied biological sciences. Psychology; Homocysteine - blood; Homocysteine - drug effects; Humans; Male; Middle Aged; Neural Tube Defects - prevention & control; Placebos; Plasma; Tetrahydrofolates - administration & dosage; Treatment Outcome; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Vitamin B; Vitamin B 12 Deficiency - diagnosis; Human; homocysteine; cardiovascular disease; Low dose; L-MTHF; Supplemented diet; Folic acid; Folate; L-5-Methyltetrahydrofolate; plasma folate; Feeding; Homocystein; Randomized design; Placebo; red blood cell folate; Clinical trial; Derived product; Comparative study
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1093/ajcn/77.3.658

Food fortification with folic acid has been introduced in several countries for the prevention of neural tube defects. Fortification has lowered total homocysteine (tHcy) concentrations in the US population, a consequence that may have health benefits. However, folic acid fortification could mask vitamin B-12 deficiency. Synthetic L-5-methyltetrahydrofolate (L-MTHF) may be more appropriate than folic acid as a fortificant because it is unlikely to mask the hematologic indicators of vitamin B-12 deficiency.
The objective of the study was to compare the effectiveness of 100 micro g folic acid/d with that of equimolar L-MTHF in lowering tHcy in healthy volunteers.
The study was designed as a 24-wk, randomized, placebo-controlled intervention. Free-living healthy volunteers (n = 167) were randomly assigned to receive a daily supplement containing folic acid (100 microg), L-MTHF (113 microg), or placebo. Blood collected at baseline and at 8, 16, and 24 wk was analyzed for tHcy, plasma folate, and red blood cell folate (RCF) concentrations.
At 24 wk, after adjustment for baseline values, mean (95% CI) tHcy was 14.6% (9.3, 19.5%) and 9.3% (3.7, 14.6%) lower, mean plasma folate was 34% (14, 56%) and 52% (30, 78%) higher, and mean RCF was 23% (12, 35%) and 31% (19, 44%) higher in the L-MTHF and folic acid groups, respectively, than in the placebo group. L-MTHF was more effective than was folic acid in lowering tHcy (P < 0.05). At 24 wk, the increases in plasma folate and RCF concentrations did not differ significantly between the 2 supplemented groups.
Low-dose L-MTHF is at least as effective as is folic acid in reducing tHcy concentrations in healthy persons.